Atlas Trials

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Clinical trial NCT06524544 · RECRUITING

Trial details

NCT number
NCT06524544
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Start date
2025-12-02
Primary completion
2028-12-31
Enrollment
320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.